Plasma viral load (pVL) is a key indicator of therapeutic response in HIV-infected patients receiving combination antiretroviral therapy (cART), but is often unavailable in routine clinical care in resource-limited settings. Previous model-based simulation studies have suggested that the benefits of routine pVL monitoring among patients on first-line regimens in resource-limited settings are modest, but this needs corroboration in well-defined study populations.
Methods
We investigated virological suppression levels and identified predictors of detectable viraemia among 870 randomly selected patients who started cART between May 2009 and April 2012 in 10 health-care facilities in Addis Ababa, Ethiopia. A total of 656 (75.4%) patients, who were alive, were retained in HIV care and receiving cART for at least 6 months provided a blood sample for pVL measurement. Predictors of detectable viraemia were identified in a multivariate logistic regression model.
Results
In on-treatment analysis, 94.5% (95% CI 92.5, 96.1) of the patients achieved virological suppression below 400 copies/ml after a median (IQR) of 26 (17–35) months on cART. When patients who were lost to follow-up, dead or stopped were assumed to have had detectable viraemia, the proportion of patients with virological suppression ≤400 copies/ml decreased to 74.6% (95% CI 71.5%, 77.4%). Younger age, lower educational status, ≤95% medication adherence, lower CD4+ T-cell count at cART initiation and/ or the diagnosis of immunological failure thereafter significantly predicted detectable viraemia.
Conclusions
Virological suppression levels can be high in an established ART programme in a resource-limited setting, even without the availability of routine pVL monitoring. Efforts to improve treatment outcomes should focus on younger and illiterate patients, earlier detection of HIV-positive status and cART initiation before patients are severely immunocompromised, and improving retention in care.
AssefaY., JereneD., LulsegedS., OomsG., Van DammeW.Rapid scale-up of antiretroviral treatment in Ethiopia: successes and system-wide effects.PLoS Med2009; 6: e1000056.
3.
AssefaY., AlebachewA., LeraM.Scaling up antiretroviral treatment and improving patient retention in care: lessons from Ethiopia, 2005–2013.Global Health2014; 10: 43.
4.
ArayaT., TensouB., DaveyG., BerhaneY.Burial surveillance detected significant reduction in HIV-related deaths in Addis Ababa, Ethiopia.Trop Med Int Health2011; 16: 1483–1489.
5.
ReniersG., ArayaT., DaveyG.Steep declines in population-level AIDS mortality following the introduction of antiretroviral therapy in Addis Ababa, Ethiopia.AIDS2009; 23: 511–518.
World Health Organization.Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. June 2013. Geneva, Switzerland. (Accessed 5 May 2015.) Available from http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf.
8.
GulickR.M., RibaudoH.J., ShikumaC.M.Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.N Engl J Med2004; 350: 1850–1861.
9.
StaszewskiS., Morales-RamirezJ.A., TashimaK.T.Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults.N Engl J Med1999; 341: 1865–1873.
10.
MontanerJ.S.G., ReissP., CooperD.A.A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS trial.JAMA1998; 279: 930–937.
11.
BarthR.E., van der LoeffM.F., SchuurmanR., HoepelmanA.I., WensingA.M.Virological follow-up of adult patients in antiretroviral treatment programs in sub-Saharan Africa: a systematic review.Lancet Infect Dis2010; 10: 155–166.
12.
McMahonJ.H., JulianH.E., BertagnolioS., KubiakR., JordanM.R.Viral suppression after 12 months of antiretroviral therapy in low- and middle-income countries: a systematic review.Bull World Health Organ2013; 91: 377–385.
13.
SchwartländerB., GrubbI., PerriensJ.The 10-year struggle to provide antiretroviral treatment to people with HIV in the developing world.Lancet2006; 368: 541–546.
14.
HamersR.L., WallisC.L., KityoC.HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of anti-retroviral therapy: a multicentre observational study.Lancet Infect Dis2011; 11: 750–759.
15.
KassaD., GebremichaelG., AlemayehuY., WoldayD., MesseleT., van BaarleD.Virologic and immunologic outcome of HAART in human immunodeficiency virus (HIV)-1 infected patients with and without tuberculosis (TB) and latent TB infection (LTBI) in Addis Ababa, Ethiopia.AIDS Res Ther2013; 10: 18.
16.
ReepaluA., BalchaT.T., SkogmarS.High rates of virological suppression in a cohort of human immunodeficiency virus-positive adults receiving antiretroviral therapy in Ethiopian health centers irrespective of concomitant tuberculosis.Open Forum Infect Dis2014; 1: ofu039.
17.
AbdissaA., YilmaD., FonagerJ.Drug resistance in HIV patients with virological failure or slow virological response to antiretroviral therapy in Ethiopia.BMC Infect Dis2014; 14: 181.
18.
UrbaniakG.C., PlousS.(2011). Research Randomizer (Version 3.0) computer software. (Accessed 10 July 2012.) Available from http://www.randomizer.org/.
19.
MekuriaL.A., SprangersM.A.G., PrinsJ.M., YalewA.W., NieuwkerkP.T.Health-related quality of life of HIV-infected adults receiving combination antiretroviral therapy in Addis Ababa.AIDS Care2015; 27: 934–945.
20.
de BoerI.M., PrinsJ.M., SprangersM.A.G., NieuwkerkP.T.Using different calculations of pharmacy refill adherence to predict virological failure among HIV-infected patients.J Acquir Immune Defic Syndr2010; 55: 635–640.
Abbott Real Time TM HIV-1/HCV: quick reference guide for manual sample preparation.Abbott GmbH & Co.KG, Abbott Molecular Europe, Max-Plank-Ring2. Wiesbaden-Delkenheim, 09/06/1.
23.
LeeP.K., KiefferT.L., SilicianoR.F., NettlesR.E.HIV-1 viral load blips are of limited clinical significance.J Antimicrob Chemother2006; 57: 803–805.
24.
Di MascioM., MarkowitzM., LouieM.Viral blip dynamics during highly active antiretroviral therapy.J Virol2003; 77: 12165–12172.
25.
SantoroM.M., ArmeniaD., AlteriC.Impact of pre-therapy viral load on virological response to modern first-line HAART.Antivir Ther2013; 18: 867–876.
26.
MekuriaL.A., PrinsJ.M., YalewA.W., SprangersM.A.G., NieuwkerkP.T.Retention in HIV care and predictors of attrition from care among HIV-infected adults receiving combination anti-retroviral therapy in Addis Ababa.PLoS ONE2015; 10: e0130649.
27.
IversL.C., KendrickD., DoucetteK.Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature.Clin Infect Dis2005; 41: 217–224.
28.
BussmannH., WesterC.W., NdwapiN.Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program.AIDS2008; 22: 2303–2311.
29.
PhillipsA.N., PillayD., MinersA.H., BennettD.E., GilksC.F., LundgrenJ.D.Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model.Lancet2008; 371: 1443–1451.
30.
KeeblerD., RevillP., BraithwaiteS.Costeffectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models.Lancet Glob Health2014; 2: e35–e43.
31.
GibbD.M., MugyenyiP.Sustainable and cost-effective monitoring of patients on ART [comment].Lancet2014; 2: e4–e5.
32.
FMoH/HAPCO (Ethiopia).HIV/AIDS related commodity requirements for the Federal Republic of Ethiopia: 2009 to 2014. (Updated December 2008. Accessed 20 May 2015.) Available from http://www.etharc.org/resources/download/finish/33/99.
HassanA.S., NabweraH.M., MwaringaS.M.HIV-1 virologic failure and acquired drug resistance among first-line antiretroviral experienced adults at a rural HIV clinic in coastal Kenya: a cross-sectional study.AIDS Res Ther2014; 11: 9.
35.
MocroftA., GillM.J., DavidsonW., PhillipsA.N.Predictors of a viral response and subsequent virological failure in patients with HIV starting a protease inhibitor.AIDS1998; 12: 2161–2167.
36.
AuldA.F., AgoloryS.G., ShiraishiR.W.Antiretroviral therapy enrollment characteristics and outcomes among HIV-infected adolescents and young adults compared with older adults-seven African countries, 2004–2013.MMWR Morb Mortal Wkly Rep2014; 63: 1097–1103.
37.
HadlandS.E., MilloyM.J., KerrT.Young age predicts poor antiretroviral adherence and viral load suppression among injection drug users.AIDS Patient Care STDS2012; 26: 274–280.
38.
LallP., LimS.H., KhairuddinN., KamarulzamanA.An urgent need for research on factors impacting adherence to and retention in care among HIV-positive youth and adolescents from key populations.J Int AIDS Soc2015; 18Suppl 1: 19393.
39.
NachegaJ.B., HislopM., NguyenH.Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in Southern Africa.J Acquir Immune Defic Syndr2009; 51: 65–71.
40.
MurphyD.A., BelzerM., DurakoS.J., SarrM., WilsonC.M., MuenzL.R.Longitudinal antiretroviral adherence among adolescents infected with human immunodeficiency virus.Arch Pediatr Adolesc Med2005; 159: 764–770.
41.
BekkerL.G., JohnsonL., WallaceM., HosekS.Building our youth for the future.J Int AIDS Soc2015; 18Suppl 1: 20027.
42.
FoxM.P., CutsemG.V., GiddyJ.The IeDEA-SA collaboration. Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa.J Acquir Immune Defic Syndr2012; 60: 428–437.
43.
UyJ., ArmonC., BuchaczK., WoodK., BrooksJ.T., HOPS Investigators. Initiation of HAART at higher CD4 cell counts is associated with a lower frequency of antiretroviral drug resistance mutations at virologic failure.J Acquir Immune Defic Syndr2009; 51: 450–453.
44.
MooreD.M., MerminJ., AworA., YipB., HoggR.S., MontanerJ.S.Performance of immunologic responses in predicting viral load suppression: implications for monitoring patients in resource-limited settings.J Acquir Immune Defic Syndr2006; 43: 436–439.
45.
LatheyJ.L., HughesM.D., FiscusS.A.Variability and prognostic values of virologic and CD4 cell measures in human immunodeficiency virus type-1 infected patients with 200–500 CD4 cells/mm3 (ACTG 175).J Infect Dis1998; 177: 617–624.
46.
AhdiehL., GangeS.J., GreenblattR.Selection by indication of potent antiretroviral therapy usage in a large cohort of HIV-infected women.Am J Epidemiol2000; 152: 923–933.
47.
ParedesR., MocroftA., KirkO.Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study.Arch Intern Med2000; 160: 1123–1132.
48.
ReynoldsS.J., NakigoziG., NewellK.Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda.AIDS2009; 23: 697–700.
49.
van OosterhoutJ.J., BrownL., WeigelR.Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteria.Trop Med Int Health2009; 14: 856–861.
50.
RawizzaH.E., ChaplinB., MeloniS.T.Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings.Clin Infect Dis2011; 53: 1283–1290.
51.
MeeP., FieldingK.L., CharalambousS., ChurchyardG.J., GrantA.D.Evaluation of WHO criteria for antiretroviral treatment failure among adults in South Africa.AIDS2008; 22: 1971–1977.
52.
PhillipsA.N., StaszewskiS., WeberR.HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load.JAMA2001; 286: 2560–2567.
53.
WHO.Treat 3 million by 2005: interim WHO clinical staging of HIV/AIDS and HIV/AIDS case definitions for surveillance, African Region (2005). Geneva. (Accessed 12 May 2015.) Available from http://www.who.int/hiv/pub/guidelines/clinicalstaging.pdf.
